Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07348367 · ClinicalTrials.gov registry record · NA

A Comparison of Radical Prostatectomy and Precision Prostatectomy in Low- and Intermediate-risk Prostate Cancers.

A NA study of Prostatectomy, sponsored by Henry Ford Health System.

Recruiting
Registry status
NA
Development phase
160
Enrollment target
1
Study location

NCT07348367: Recruiting NA study of Prostatectomy, sponsored by Henry Ford Health System.

NCT07348367 is a NA study of Prostatectomy that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 160 participants, above the 91-participant average among 4 other Prostatectomy trials with a reported enrollment target (76% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07348367, a NA study of Prostatectomy, is actively recruiting participants, sponsored by Henry Ford Health System.

RECRUITING
Registry status
NA
Development phase
160 participants
Enrollment target
1
Study location

Study Summary

Prostate cancer (PCa) management for low- and intermediate-risk patients often involves radical prostatectomy (RP), which achieves oncologic control but is associated with significant functional impairments, such as erectile dysfunction (50-70%) and urinary incontinence (5-20%). To address these issues, precision prostatectomy (PP) has emerged as a novel surgical approach that preserves functional structures while removing \>90% of prostate tissue. PP is thought to provide superior functional outcomes with acceptable oncological control by preserving the capsule, seminal vesicle (SV), and the surrounding neuronal nitric oxide synthase (nNOS) producing nerves on the side opposite to the dominant nodule while maximizing prostatic tissue removal. Early reports of PP demonstrate promising functional outcomes, with 90% of patients retaining sexual potency (Sexual Health Inventory for Men \[SHIM\] score ≥17) and 100% achieving continence (0-1 pads/day) by 12 months postoperatively. Importantly, PP only requires a different surgical technique, no more equipment, time, or labor is required. This means that there is no additional charge to patients, and it is covered the same by health insurance. While there are early results suggesting the superiority of PP, no randomized trials have yet to be performed. This study has two main aims: to demonstrate superiority of PP in terms of functional recovery while also establishing non-inferiority in oncologic outcomes compared to RP. This dual objective reflects the potential of PP to improve quality of life without compromising cancer control. Eligible patients will be randomized to either RP, which is the current standard of care, or PP using random blocked randomization using the Zelen design. The outcomes of interest will be measured at 12 months post-surgery. Functional outcomes will be measured using SHIM scores at 12 months and the number of pads used per day. Meanwhile, oncological outcomes will be measured by whether pat

Primary Outcome

Patients' sexual health and function is measured by the Sexual Health Inventory for Men (SHIM). A SHIM score \> 16 is considered sexually healthy.

Conditions Studied

Interventions

  • PROCEDURE Radical Prostatectomy
  • PROCEDURE Precision Prostatectomy

Study Locations (1)

Michigan

  • Henry Ford Health - Detroit

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2026-01-12
Est. Completion 2028-12
Phase NA
Henry Ford Health System

234 total trials

What NCT07348367 shows while recruiting

NCT07348367 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 91-participant average among 4 other Prostatectomy trials with a reported enrollment target (76% higher).

The record links to 1 condition, with Prostatectomy appearing as the primary indexed condition, and to 2 interventions - of which Radical Prostatectomy is the first listed.

NCT07348367 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT07348367 about?

NCT07348367 is a clinical study titled "A Comparison of Radical Prostatectomy and Precision Prostatectomy in Low- and Intermediate-risk Prostate Cancers.". Prostate cancer (PCa) management for low- and intermediate-risk patients often involves radical prostatectomy (RP), which achieves oncologic control but is associated with significant functional impairments, such as erectile dysfunction (50-70%) and urinary incontinence (5-20%). To address these iss...

What is the current status of trial NCT07348367?

This trial is currently recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2026-01-12. Estimated completion is 2028-12.

What conditions does trial NCT07348367 study?

This clinical trial studies the following conditions: Prostatectomy.

What interventions are being tested in trial NCT07348367?

The interventions under investigation include: Radical Prostatectomy (PROCEDURE), Precision Prostatectomy (PROCEDURE).

Who is sponsoring clinical trial NCT07348367?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07348367 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostatectomy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00501826 · 160 participants · Phase 2

    Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • NCT00932139 · 160 participants · NA

    Effect of Electro-Acupuncture on Blood Pressure

  • NCT00992901 · 160 participants · Early Phase 1

    Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

  • NCT01515527 · 160 participants · Phase 2

    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07348367, the US trial registry maintained by the National Library of Medicine. NCT07348367 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.